Bone Metastasis from Renal Cell Carcinoma
AbstractAbout one-third of patients with advanced renal cell carcinoma (RCC) have bone metastasis that are often osteolytic and cause substantial morbidity, such as pain, pathologic fracture, spinal cord compression and hypercalcemia. The presence of bone metastasis in RCC is also associated with poor prognosis. Bone-targeted treatment using bisphosphonate and denosumab can reduce skeletal complications in RCC, but does not cure the disease or improve survival. Elucidating the molecular mechanisms of tumor-induced changes in the bone microenvironment is needed to develop effective treatment. The “vicious cycle” hypothesis has been used to describe how tumor cells interact with the bone microenvironment to drive bone destruction and tumor growth. Tumor cells secrete factors like parathyroid hormone-related peptide, transforming growth factor-β and vascular endothelial growth factor, which stimulate osteoblasts and increase the production of the receptor activator of nuclear factor κB ligand (RANKL). In turn, the overexpression of RANKL leads to increased osteoclast formation, activation and survival, thereby enhancing bone resorption. This review presents a general survey on bone metastasis in RCC by natural history, interaction among the immune system, bone and tumor, molecular mechanisms, bone turnover markers, therapies and healthcare burden. View Full-Text
Share & Cite This Article
Chen, S.-C.; Kuo, P.-L. Bone Metastasis from Renal Cell Carcinoma. Int. J. Mol. Sci. 2016, 17, 987.
Chen S-C, Kuo P-L. Bone Metastasis from Renal Cell Carcinoma. International Journal of Molecular Sciences. 2016; 17(6):987.Chicago/Turabian Style
Chen, Szu-Chia; Kuo, Po-Lin. 2016. "Bone Metastasis from Renal Cell Carcinoma." Int. J. Mol. Sci. 17, no. 6: 987.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.